<DOC>
	<DOCNO>NCT01782742</DOCNO>
	<brief_summary>Retinoid X receptor ( RXR ) nuclear receptor link numerous metabolic pathway relevant Alzheimer 's disease ( AD ) Aβ ( harmful protein ) production removal . The study drug `` bexarotene '' FDA approve anti-cancer agent approve use Alzheimer 's disease . Bexarotene act RXR agonist reduce Aβ ( harmful protein ) brain experimental model Alzheimer 's disease . This study aim determine safety effect abnormal protein find brain ( base brain scan ) 300 mg `` bexarotene '' administer one month compare placebo ( inactive agent ) .</brief_summary>
	<brief_title>Bexarotene Amyloid Treatment Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Bexarotene</mesh_term>
	<criteria>Males females 50 90 age inclusive . Diagnosis probable AD accord National Institute Neurological Communicative Disorders StrokeAlzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion . Willing able provide inform consent either subject subject 's legal representative . Willing able comply study visit , treatment plan , laboratory test , brain imaging procedure . Subjects must positive 18fAV45 PET scan determine qualified rater . MiniMental State Examinations ( MMSE ) score 1020 inclusive . Must study partner able willing comply require study procedure . Females must postmenopausal . Have least eight year education previously ( preAD condition ) capable reading , write , communicate effectively others English . If receive therapy cholinesterase inhibitor and/or memantine , dose agent stable least 4 week prior randomization Normal laboratory finding baseline include CBC , chemistry panel , serum lipid , liver function , TSH , vitamin B12 . Must consent ApoE genotyping Any clinically relevant neurological disorder capable produce dementia syndrome include Parkinson 's disease , stroke , vascular dementia , dementia Lewy body , frontotemporal dementia others . 4 microhemorrhages ( amyloidrelated image abnormality hemorrhage type ( ARIAH ) baseline MRI evidence amyloidrelated image abnormality effusion type ( ARIAE ) ( Sperling et al , 2011 ) . History malignancy within past five year exception basal cell squamous cell cancer , insitu cervical cancer , localize prostate cancer . History seizure past three year prior randomization Any contraindication brain MRI Any contraindication PET ( inability lie flat still duration scan , intolerance previous PET hypersensitivity reaction PET ligand image agent ) The subject unstable medical illness include hypertension , congestive heart failure , chronic obstructive pulmonary disease , renal failure , liver failure organ compromise . Other clinically important abnormality vital sign , physical examination , neurologic examination , laboratory result , electrocardiogram ( ECG ) examination ( e.g . Atrial fibrillation ) could compromise study detrimental subject . The subject receive bexarotene previously . The subject allergy bexarotene . Has PET scan past 12 month . Has radiotherapy past year . Have participate investigational drug device study within 30 day prior Visit 2 . Have treat immunomodulators treat AD ( vaccine , antibody etc ) within 6 month prior visit 2 Unable swallow uncrushed oral medication capsule form Have condition reason , opinion investigator , could interfere ability patient participate complete trial , place patient undue risk complicates interpretation safety efficacy data .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Mild Moderate Alzheimer 's Disease</keyword>
</DOC>